HUE055083T2 - Tiszta 5-HT6 receptor antagonisztika kombinációja az NMDA receptor antagonistájával - Google Patents
Tiszta 5-HT6 receptor antagonisztika kombinációja az NMDA receptor antagonistájávalInfo
- Publication number
- HUE055083T2 HUE055083T2 HUE16766623A HUE16766623A HUE055083T2 HU E055083 T2 HUE055083 T2 HU E055083T2 HU E16766623 A HUE16766623 A HU E16766623A HU E16766623 A HUE16766623 A HU E16766623A HU E055083 T2 HUE055083 T2 HU E055083T2
- Authority
- HU
- Hungary
- Prior art keywords
- pure
- combination
- receptor
- nmda
- receptor antagonist
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 title 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017203 | 2016-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE055083T2 true HUE055083T2 (hu) | 2021-10-28 |
Family
ID=56940099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16766623A HUE055083T2 (hu) | 2016-05-18 | 2016-08-03 | Tiszta 5-HT6 receptor antagonisztika kombinációja az NMDA receptor antagonistájával |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11116764B2 (hu) |
| EP (1) | EP3458040B1 (hu) |
| JP (1) | JP6606298B2 (hu) |
| KR (1) | KR102023748B1 (hu) |
| CN (1) | CN109069449A (hu) |
| AU (1) | AU2016407428B2 (hu) |
| BR (1) | BR112018073396A2 (hu) |
| CA (1) | CA3023828C (hu) |
| DK (1) | DK3458040T3 (hu) |
| EA (1) | EA036301B1 (hu) |
| HK (1) | HK1258023A1 (hu) |
| HR (1) | HRP20210640T1 (hu) |
| HU (1) | HUE055083T2 (hu) |
| IL (1) | IL262816B (hu) |
| MX (1) | MX2018013969A (hu) |
| NZ (1) | NZ747778A (hu) |
| SG (1) | SG11201809725TA (hu) |
| WO (1) | WO2017199072A1 (hu) |
| ZA (1) | ZA201807311B (hu) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201913104QA (en) * | 2017-07-03 | 2020-01-30 | Suven Life Sciences Ltd | New uses of a pure 5-ht 6 receptor antagonist |
| WO2021111320A1 (en) | 2019-12-02 | 2021-06-10 | Suven Life Sciences Limited | Methods for treating behavioral and psychological symptoms in patients with dementia |
| EP4069232A1 (en) * | 2019-12-02 | 2022-10-12 | Suven Life Sciences Limited | Treating behavioral and psychological symptoms in dementia patients |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE401307T1 (de) * | 2002-11-28 | 2008-08-15 | Suven Life Sciences Ltd | N-arylsulfonyl-2-substituierte indole mit affinität zum serotonin rezeptor, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen |
| EP1902733A1 (en) * | 2006-09-19 | 2008-03-26 | Laboratorios Del Dr. Esteve, S.A. | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity |
| RS56323B1 (sr) | 2013-12-02 | 2017-12-29 | Suven Life Sciences Ltd | Proces za masovnu proizvodnju monohidrata 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1h-indol dimezilata |
-
2016
- 2016-08-03 WO PCT/IB2016/054674 patent/WO2017199072A1/en active Search and Examination
- 2016-08-03 KR KR1020187035901A patent/KR102023748B1/ko active IP Right Grant
- 2016-08-03 CA CA3023828A patent/CA3023828C/en active Active
- 2016-08-03 MX MX2018013969A patent/MX2018013969A/es unknown
- 2016-08-03 US US16/097,458 patent/US11116764B2/en active Active
- 2016-08-03 EA EA201892583A patent/EA036301B1/ru unknown
- 2016-08-03 SG SG11201809725TA patent/SG11201809725TA/en unknown
- 2016-08-03 HU HUE16766623A patent/HUE055083T2/hu unknown
- 2016-08-03 DK DK16766623.9T patent/DK3458040T3/da active
- 2016-08-03 EP EP16766623.9A patent/EP3458040B1/en active Active
- 2016-08-03 JP JP2018559283A patent/JP6606298B2/ja active Active
- 2016-08-03 BR BR112018073396-2A patent/BR112018073396A2/pt not_active Application Discontinuation
- 2016-08-03 NZ NZ747778A patent/NZ747778A/en unknown
- 2016-08-03 CN CN201680085559.6A patent/CN109069449A/zh active Pending
- 2016-08-03 AU AU2016407428A patent/AU2016407428B2/en active Active
-
2018
- 2018-10-31 ZA ZA2018/07311A patent/ZA201807311B/en unknown
- 2018-11-06 IL IL262816A patent/IL262816B/en active IP Right Grant
-
2019
- 2019-01-10 HK HK19100394.1A patent/HK1258023A1/zh unknown
-
2021
- 2021-04-22 HR HRP20210640TT patent/HRP20210640T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL262816B (en) | 2020-05-31 |
| CA3023828C (en) | 2019-08-27 |
| MX2018013969A (es) | 2019-03-21 |
| US11116764B2 (en) | 2021-09-14 |
| HRP20210640T1 (hr) | 2021-06-25 |
| BR112018073396A2 (pt) | 2019-03-19 |
| SG11201809725TA (en) | 2018-12-28 |
| KR102023748B1 (ko) | 2019-09-20 |
| HK1258023A1 (zh) | 2019-11-01 |
| NZ747778A (en) | 2020-03-27 |
| WO2017199072A1 (en) | 2017-11-23 |
| JP2019516696A (ja) | 2019-06-20 |
| CA3023828A1 (en) | 2017-11-23 |
| EP3458040B1 (en) | 2021-01-27 |
| CN109069449A (zh) | 2018-12-21 |
| AU2016407428A1 (en) | 2018-11-29 |
| JP6606298B2 (ja) | 2019-11-13 |
| EA201892583A1 (ru) | 2019-04-30 |
| IL262816A (en) | 2018-12-31 |
| ZA201807311B (en) | 2020-01-29 |
| EA036301B1 (ru) | 2020-10-23 |
| EP3458040A1 (en) | 2019-03-27 |
| AU2016407428B2 (en) | 2019-11-21 |
| US20190175586A1 (en) | 2019-06-13 |
| DK3458040T3 (da) | 2021-05-03 |
| KR20180136566A (ko) | 2018-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258892B (en) | Calcitonin gene-related peptide receptor antagonists | |
| HK1249095A1 (zh) | Cgrp受體拮抗劑 | |
| IL258894A (en) | Cgrp receptor antagonists | |
| IL262921B (en) | Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors | |
| HK1258023A1 (zh) | 純5-ht6受體拮抗劑與nmda受體拮抗劑的組合 | |
| IL271694A (en) | Novel uses of a pure 6HT–5 receptor antagonist | |
| HK1258022A1 (zh) | 純5-ht6受體拮抗劑、乙醯膽鹼酯酶抑制劑和nmda受體拮抗劑的三重組合 | |
| IL258893A (en) | Cgrp receptor antagonists | |
| ZA202000758B (en) | Fluoropiperidine compounds as pure 5-ht6 receptor antagonists | |
| GB201513871D0 (en) | Bicyclo dopamine D3 receptor antagonists |